Navigation Links
Transgenomic Appoints David Pauluzzi to Board of Directors
Date:2/5/2008

Former Quest Executive Director Brings Extensive Strategic Marketing

Expertise

OMAHA, Neb., Feb. 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), today announced that it has appointed David P. Pauluzzi to its Board of Directors. Mr. Pauluzzi is currently a consultant at Water Street Healthcare Partners, a Chicago-based private equity firm specializing in the healthcare sector.

Prior to his current position, Mr. Pauluzzi served as Executive Director/VP of Quest Diagnostics, the nation's leading provider of diagnostic testing, information and services, where he directed operations, marketing and sales for its Esoteric Anatomic Pathology Business and built a direct sales and marketing organization for its Hospital Division. He also served as V.P. of Sales and Marketing and Chief Operating Officer for US LABS, a national anatomic pathology reference laboratory, where he hired and developed the Company's sales and marketing organization and launched national marketing and re-branding initiatives. Mr. Pauluzzi has also served as Senior Director of World Wide Marketing for Ventana Medical Systems, a global leader in tissue- based cancer diagnostics, and as District Sales Manager and International Marketing Manager for the Diagnostics Division of global healthcare company Abbott Laboratories.

Craig Tuttle, Transgenomic President and Chief Executive Officer, stated, "Mr. Pauluzzi brings more than 20 years of worldwide diagnostic and clinical laboratory experience with both leading and emerging healthcare service companies that includes extensive expertise in strategic marketing, developing and managing sales organizations, and senior level diagnostic product and systems sales. His cancer diagnostic and services industry experience includes anatomic pathology, genomics, proteomics and the pharmacogenomics market serving physicians, labs and hospitals. We are excited to have him join the Company's Board of Directors."

About Transgenomic:

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics Research Services. Transgenomic's two laboratory services divisions utilize these technologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


'/>"/>
SOURCE Transgenomic Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast
3. Transgenomic, Inc. Forms Scientific Advisory Board
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Codexis Appoints Singapore Laboratories Managing Director
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
10. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):